Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237925 | 0.89 | GPR119 (0.44) | GPR119DPP4GRIA1OPRD1OPRK1 | |
| SCHEMBL11356927 | 0.72 | HRH3 (0.56) | GPR119GRIA1KIT | |
| SCHEMBL20607545 | 0.70 | AOC3 (0.54) | GPR119GRIA1ACHEKITCXCR2 | |
| SCHEMBL2414006 | 0.70 | GPR119 (0.47) | GPR119DPP4GRIA1ACHEKIT | |
| SCHEMBL2420435 | 0.69 | GPR119 (0.52) | GPR119GRIA1KIT | |
| SCHEMBL30893588 | 0.69 | GPR119 (0.52) | GPR119GRIA1KIT | |
| SCHEMBL5332037 | 0.69 | MC4R (0.54) | GPR119OPRD1OPRK1ACHEKIT | |
| SCHEMBL21937028 | 0.69 | MAPT (0.51) | GPR119DPP4HTT | |
| SCHEMBL31652230 | 0.69 | GPR119 (0.48) | GPR119GRIA1ACHEKITCXCR2 | |
| SCHEMBL5337806 | 0.69 | OPRD1 (0.48) | GPR119OPRD1OPRK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | GPR119 83/4885DPP4 2805/4885GRIA1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.